Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 15/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24120771 | 0.83 | IDH1 (0.62) | IDH1DAOLMNAPKM | |
| SCHEMBL17770627 | 0.80 | IDH1 (0.60) | IDH1 | |
| SCHEMBL24120703 | 0.78 | IDH1 (0.53) | IDH1 | |
| SCHEMBL24120736 | 0.78 | IDH1 (0.53) | IDH1GABRA1GABRB2 | |
| SCHEMBL15112068 | 0.77 | IDH1 (0.56) | IDH1 | |
| SCHEMBL16093372 | 0.76 | CA12 (0.38) | IDH1GABRA1GABRB2LMNA | |
| SCHEMBL13193519 | 0.74 | ALDH1A1 (0.39) | IDH1GABRA1GABRB2LMNA | |
| SCHEMBL24120709 | 0.74 | IDH1 (0.53) | IDH1LMNA | |
| SCHEMBL24120715 | 0.74 | IDH1 (0.53) | IDH1LMNA | |
| SCHEMBL27016819 | 0.72 | IDH1 (0.38) | IDH1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | IDH1 613/4885DAO 1644/4885GABRA1 1631/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | IDH1 613/4885DAO 1644/4885GABRA1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.